CP
MRTX

Castleview Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Castleview Partners’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5
Closed -$226 – 724
2022
Q4 		$226 Buy
+5
New +$324 ﹤0.01% 613

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Castleview Partners's MRTX Position: Q1 2023 in Review

Castleview Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2023, closing a stake of 5 shares — an estimated $226 sold.

Castleview Partners first reported a position in MRTX in Q4 2022 and held it in 1 quarter. The position peaked at $226 in Q4 2022. 221 funds tracked by Wall St. Rank hold MRTX as of Q1 2023.

  • Castleview Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Castleview Partners sold 5 Mirati Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $226.
  • Castleview Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Castleview Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $226 in Q4 2022.
  • 221 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Castleview Partners's 13F filing for Q1 2023, filed 16 May 2023.